ASM Microbe 2019 Conference Grants Both Poster and Oral Presentations to CytoDyn for its Pivotal Study of Leronlimab (PRO 140) which Demonstrated Superior Efficacy and Safety in Heavily Treatment-Experienced HIV Patients
Stock Information for Cytodyn Inc
Loading
Please wait while we load your information from QuoteMedia.